Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 604-610 , November 2009

Treatment of a population based sample of men diagnosed with testicular cancer in the United States

  • Michael Osswald, M.D.

      Affiliations

    • Department of Medicine, Lackland Air Force Base, San Antonia, TX 78236, USA
    • ,
  • Linda C. Harlan, Ph.D.

      Affiliations

    • Applied Research Program, DCCPS, National Cancer Institute, Bethesda, MD 20892, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-301-496-7085; fax: +1-301-435-3710
    • ,
  • David Penson, M.D.

      Affiliations

    • Department of Urology and Preventive Medicine, University of Southern California, Los Angeles, CA 90089, USA
    • ,
  • Jennifer L. Stevens, B.S.

      Affiliations

    • Information Management Services, Silver Spring, MD 20904, USA
    • ,
  • Limin X. Clegg, Ph.D.

      Affiliations

    • Office of Healthcare Inspections, Office of Inspector General, Department of Veterans Affairs, Washington, DC 20001, USA

Received 29 April 2008 ,Revised 13 June 2008 ,Accepted 17 June 2008.

References 

  1. American Cancer Society. Cancer facts and figures 2008. In: Atlanta (GA): American Cancer Society; 2007;p. 4
  2. McGlynn KA, Devesa SS, Graubard BI, et al. Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol. 2005;23:5757–5761
  3. National Cancer Institute. SEER cancer statistics review 1975–2003. http://seer.cancer.gov/csr/1975_2003/results_merged/sect_25_testis.pdfAccessed August 29, 2008
  4. National Cancer Institute. SEER Program: Comparative staging guide for cancer. http://seer.cancer.gov/manuals/historic/comp_stage1.1.pdfAccessed August 29, 2008
  5. Shah BV, Barnwall BG, Bieler GS. SUDAAN. In: Research Triangle Park (NC): Research Triangle Institute; 1997;p. 10–11
  6. Schmoli HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Onc. 2004;15:1377–1399
  7. Oliver RTD, Mason MD, Mead GM, et al. Radiotherapy vs. single-dose carboplatin in adjuvant treatment of Stage I seminoma: A randomized trial. Lancet. 2005;366:293–300
  8. Segal R. Surveillance programs for Stage I nonseminomatous germ cell tumors of the testis. Urol Oncol. 2006;24:68–74
  9. Steele GS, Richie JP, Stewart AK, et al. The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985–1996. Cancer. 1999;86:2171–2183
  10. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (Testicular cancer). http://www.nccn.org/professionals/physicians_gls/PDF/testicular.pdfAccessed August 29, 2008
  11. Gilbert DC, Norman AR, Nicholl J, et al. Treating Stage I nonseminomatous germ cell tumors with a single cycle of chemotherapy. BJU Int. 2006;98:67–69
  12. Mezvrishvili Z, Managadze L. One cycle of bleomycin, etoposide, and cisplatin plus two cycles of etoposide and cisplatin chemotherapy in selected patients with low-volume Stage II nonseminomatous germ cell tumor of the testis. Urol Int. 2005;75:304–308
  13. Oliver RTD, Ong J, Shamash J, et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance vs. patients with Stage I nonseminoma treated with adjuvant chemotherapy. Urology. 2004;63:556–561
  14. Horwich A, Sleijfer DB, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. 1997;15:1844–1852
  15. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multi-institutional study. J Clin Oncol. 1993;11:593–595
  16. Ozer H, Armitage JO, Bennett CL, et al. American Society of Clinical Oncology 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines (American Clinical Oncology, Growth Factors Expert Panel). J Clin Oncol. 2000;18:3558–3585
  17. van Dijk , Steyerberg EW, Habbema JDF. Survival of nonseminomatous germ cell cancer patients according to the IGGG classification: An update based on meta-analysis. Eur J Cancer. 2006;42:820–826

☆ Funded by National Cancer Institute N01-PC-35133, N01-PC-35135, N01-PC-35136, N01-PC-35137, N01-PC-35138, N01-PC-35139, N01-PC-35141, N01-PC-35142, N01-PC-35143, N01-PC-35145, N02-PC-15105, N02-PC-15106, N02-PC-15107.

PII: S1078-1439(08)00154-3

doi: 10.1016/j.urolonc.2008.06.004

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 604-610 , November 2009

Article Tools